- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04181749
Peri-vascular Adipose Tissue Inflammation Evaluated Using Coronary CT Angiography (P-VECT)
Peri-vascular Adipose Tissue Inflammation Evaluated Using Coronary CT
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Alexander
- Phone Number: 3839 0116 2583839
- Email: donna.alexander@uhl-tr.nhs.uk
Study Locations
-
-
-
Leicester, United Kingdom, LE3 9QP
- Recruiting
- University Hospitals of Leicester
-
Contact:
- Donna Alexander
- Phone Number: 0116 2583839
- Email: donna.alexander@uhl-tr.nhs.uk
-
Principal Investigator:
- David Adlam
-
London, United Kingdom, SW3 6NP
- Recruiting
- Royal Brompton Hospitals Trust
-
Contact:
- Ciara Mahon
- Phone Number: 07500697686
- Email: C.Mahon@rbht.nhs.uk
-
Principal Investigator:
- Edward Nicol
-
Oxford, United Kingdom, OX3 9DU
- Recruiting
- John Radcliffe Hospital
-
Contact:
- Vicky Toghill
- Phone Number: 07969 203252
-
Principal Investigator:
- Charalambos Antoniades
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants must satisfy the following conditions:
- Male or Female, aged 30 to 80 years,
- CCTA scan showing mild coronary artery plaques (<50% luminal stenosis) with a high FAI value (>70.1 HU) within last 3 months.
- No definite clinical indication for statin treatment (i.e. do not have either cholesterol >6.5 mM, or cholesterol >5.0 mM and QRISK score >10%).
- Clinical equipoise for statin and aspirin treatment, as determined by the local treating physician. In these patients, there is clinical equipoise because routine treatment with aspirin and statin is not mandated by current guidelines, but the presence of minor coronary artery plaques is frequently interpreted by clinicians as an indication for aspirin and statin treatment. Accordingly, some patients in this group typically receive aspirin and statin treatment, whereas others do not.
- Willing and able (in the Investigators opinion) to comply with all study requirements.
- Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of any incidental findings.
Able to understand both verbal or written English
-
Exclusion Criteria:
The participant may not enter the study if ANY of the following are known to apply:
Previous documented history of coronary artery disease requiring treatment. This includes any of the following:
Acute myocardial infarction Unstable angina Coronary revascularization procedure Clinically significant coronary artery disease diagnosed by invasive or non-invasive testing.
- Known diabetes mellitus
- Definite clinical indication for statin treatment (i.e. has either cholesterol >6.5 mM, or cholesterol >5.0 mM and QRISK score >10%).
- Treatment with aspirin, statin or any prescribed lipid modification therapy in 6 weeks before baseline CCTA
- Atrial fibrillation (paroxysmal or persistent)
- History of New York Heart Association (NYHA) Class III or IV heart failure within the past 12 months of consent.
- Autoimmune disease requiring immunosuppressive therapy or systemic corticosteroid therapy
- Active treatment with any anti-inflammatory agents (e.g. NSAIDs, corticosteroids)
- Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12 months (subjects with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to screening with no detectable recurrence are allowed)
- Contraindication for aspirin and/or statin therapy
- Severe Chronic kidney disease (estimated glomerular filtration rate < 30 mL/min/1.73 m² and/or serum creatinine > 2.5 mg/dL or 220 µmol/l).
- Hepatic dysfunction (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] > 3 × the upper limit of normal [ULN] measured on local labs in last 6 months)
- Any clinically significant abnormality identified at the time of screening that, in the opinion of the Investigator, would preclude safe completion of the study.
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Participants who have participated in another research study involving a treatment intervention or an investigational product, in the past 12 weeks.
- Patients unable to understand verbal or written English.
- Contraindication to contract dye for CCTA.
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No treatment
Patients will not be prescribed aspirin and statin
|
|
Active Comparator: Aspirin and Atorvastatin
Patients prescribed aspirin and atorvastatin
|
Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate ability of new coronary CT angiogram (CCTA) scan biomarker- Fat Attenuation Index (FAI).
Time Frame: 3year study- Two years recruitment with 8 month patient follow up
|
The overall objective is to evaluate the ability of a new cardiac CCTA scan technique, fat attenuation index (FAI), to detect changes in coronary artery perivascular fat inflammation following 8 months treatment with atorvastatin and aspirin medication
|
3year study- Two years recruitment with 8 month patient follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the association between changes in Fat Attenuation Index (FAI) and plasma lipid parameters.
Time Frame: 3year study- Two years recruitment with 8 month patient follow up
|
Evaluate this association by measuring the % of change in plasma LDL-c.
|
3year study- Two years recruitment with 8 month patient follow up
|
Evaluate the association between changes in Fat Attenuation Index (FAI) and plasma lipid parameters.
Time Frame: 3year study- Two years recruitment with 8 month patient follow up
|
Evaluate this association by measuring the % of change in plasma HDL-c.
|
3year study- Two years recruitment with 8 month patient follow up
|
Evaluate the association between changes in Fat Attenuation Index (FAI) and plasma lipid parameters.
Time Frame: 3year study- Two years recruitment with 8 month patient follow up
|
Evaluate this association by measuring the % of change in triglycerides.
|
3year study- Two years recruitment with 8 month patient follow up
|
Evaluate the association between changes in FAI and plasma biomarkers of inflammation.
Time Frame: 3year study- Two years recruitment with 8 month patient follow up
|
Evaluate this association by measuring the % of change in plasma IL-6.
|
3year study- Two years recruitment with 8 month patient follow up
|
Evaluate the association between changes in FAI and plasma biomarkers of inflammation.
Time Frame: 3year study- Two years recruitment with 8 month patient follow up
|
Evaluate this association by measuring the % of change in plasma high sensitivity C-reactive protein (hsCRP) .
|
3year study- Two years recruitment with 8 month patient follow up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Adlam, Dr., University Hospitals of Leicester and University of Leicester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Inflammation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Aspirin
- Atorvastatin
Other Study ID Numbers
- 0719
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Risk Factor
-
University of Southern DenmarkRegion of Southern Denmark; Odense Patient Data Explorative Network; ENIGMA Solutions... and other collaboratorsActive, not recruitingCardiovascular Risk Factor | Risk CommunicationDenmark
-
University of Split, School of MedicineCompletedCardiovascular Risk Factor | Lifestyle Risk ReductionCroatia
-
University Hospital, BrestRecruiting
-
University Hospitals Cleveland Medical CenterRecruitingCardiovascular Risk FactorUnited States
-
Northwestern UniversityNorthShore University HealthSystem; Case Western Reserve University; Shirley... and other collaboratorsCompleted
-
University of ArizonaTerminatedCardiovascular Risk FactorUnited States
-
Penn State UniversityCompletedCardiovascular Risk FactorUnited States
-
Clinique BizetCompleted
-
University Hospital, BrestCompleted
-
University of DelawareCompleted
Clinical Trials on aspirin and atorvastatin
-
Fox Chase Cancer CenterRecruiting
-
Anhui Medical UniversityRecruitingCognitive Impairment | Intracranial Atherosclerosis | Cerebrovascular EventChina
-
Fundacion GESICACompletedDiabetes MellitusArgentina
-
NYU Langone HealthCompletedMyocardial Infarction | Cardiovascular Diseases | Atherosclerotic Cardiovascular Disease | Thrombotic Vascular DiseaseUnited States
-
Beijing Tiantan HospitalMinistry of Science and Technology of the People's Republic of ChinaActive, not recruitingTransient Ischemic Attack | Acute StrokeChina
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
-
Dr. med. Mahir KarakasTerminatedAcute Chest SyndromeGermany
-
University of Roma La SapienzaUnknown
-
Organon and CoCompleted
-
Peking Union Medical College HospitalCompleted